Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 14/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30664857 | 1.00 | CFTR (0.48) | CFTRNOTUMPTPN2NPSR1SOS1 | |
| SCHEMBL31214172 | 0.84 | NOTUM (0.43) | CFTRNOTUMPTPN2NPSR1SOS1 | |
| SCHEMBL25359695 | 0.80 | NPSR1 (0.45) | CFTRNPSR1 | |
| SCHEMBL25262355 | 0.79 | SOS1 (0.48) | CFTRNOTUMPTPN2SOS1 | |
| SCHEMBL30500676 | 0.79 | SOS1 (0.48) | CFTRNOTUMPTPN2SOS1 | |
| SCHEMBL2373012 | 0.79 | CFTR (0.70) | CFTRNOTUM | |
| SCHEMBL29699252 | 0.79 | CFTR (0.70) | CFTRNOTUM | |
| SCHEMBL25305491 | 0.79 | NOTUM (0.40) | CFTRNOTUMPTPN2NPSR1SOS1 | |
| SCHEMBL30475035 | 0.79 | NOTUM (0.40) | CFTRNOTUMPTPN2NPSR1SOS1 | |
| SCHEMBL25305744 | 0.78 | NPSR1 (0.44) | CFTRNPSR1SOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270206-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | NNSA | 2025-08-28 | — | — | US | disclosed |
| US-20250084079-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | LEIDOS BIOMEDICAL RESEARCH, INC. | 2025-03-13 | — | — | US | disclosed |
| WO-2023225252-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | THERAS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225252-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | THERAS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023133183-A1 | KRAS INHIBITORS | THERAS, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023133183-A1 | KRAS INHIBITORS | THERAS, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084079-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | KRAS, NRAS, HRAS | CFTR 227/4885NOTUM 3861/4885PTPN2 518/4885 |
| US-20250270206-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | KRAS, NRAS, HRAS | CFTR 207/4885NOTUM 4156/4885PTPN2 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.